Respirix Develop Portable, Handheld Device For At-Home Monitoring Of Heart Failure Patients

Respirix Develop Portable, Handheld Device For At-Home Monitoring Of Heart Failure Patients
Heart failure is a staggering clinical and public health problem, associated with significant mortality, morbidity and healthcare expenditures. While there has been major progress in reducing mortality rates, hospitalizations remain frequent and readmission rates continue to rise. One of the greatest challenges in the management of patients diagnosed with heart failure is forecasting and preventing the development of acute worsening leading to hospitalization. Despite current best practice guidelines, re-hospitalization for heart failure occurs at a rate of close to 50% over 6 months.

The major reason for this unacceptably high rate is the failure to detect hemodynamic congestion prior to symptom onset. Specialized equipment that measure changes in pulmonary artery pressure (PAP) and stroke volume (SV) have shown to detect changes is cardiac function relatively early, but is not feasible for at-home use. And while implantable sensors have shown to provide clinicians with a remote monitoring tool to determine when medication adjustments are needed, the cost and invasive nature of the device severely restricts its adoption.

The San Francisco-based startup Respirix has developed Cardiospire, a portable handheld device for noninvasive at-home monitoring of heart failure patients. Their approach involves using precise analysis of breathe exhalation to monitor cardiogenic oscillations, which research suggests may be a more sensitive indicator of fluid status than invasive pulmonary artery pressure. Through easy to follow steps, the user takes a medium deep breath into the device until it indicates when it has taken a measurement. The electronically processed data is then transmitted to the physician’s office, which can be used to tailor drug dosing to correct fluid balance and optimize cardiac function in order to prevent hospitalizations.

Heart failure is the leading cause of hospitalization in patients over 65. Research shows that fast detection and intervention for patients with worsening condition dramatically reduce hospitalization and mortality. Unfortunately, there is no optimal solution to closely monitor these patients. Either they don’t keep patients out of the hospital, or they are too expensive. Respirix has designed and developed an innovative device that enable at-home monitoring of cardiac function. While other devices currently on the market have to be implanted, Cardiospire allow noninvasive extraction of the same biometric signals from hands and respiration, and at a much lower cost. The device, combined with the digital health platform that send data directly to the physician, allow remote monitoring, potentially increasing access to care. Most importantly, it is a low-cost solution that can reduce hospitalizations and readmission rates, improving health outcomes and quality of life.

Respirix is a spin-out from TheraNova, and the startup is working with Ethnonova to evaluate options for adapting Cardiospire in emerging markets, in settings with limited access to hospitals and doctors. They have previously received over $300,000 from SBIR, and in 2016 raised $800,000 from Synergy Ventures and Signatures Capital.